医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SpinalCyte, LLC Receives New Chinese Patent for Spinal Disc Tissue Engineering

2016年01月08日 PM11:12
このエントリーをはてなブックマークに追加


 

HOUSTON

SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Chinese Patent No. ZL 201110261353.3, “Method Of Differentiating Human Dermal Fibroblasts Into Chondrocyte-Like Cells Using Mechanical Strain.” The technology described in the patent involves incoporating a three dimensional matrix to expose the fibroblasts to a mechanical strain using intermittent hydrostatic pressure and/or fluid shear stress. Other claims provide for exposing the cells to hypoxia, growth factors and ascorbic acid.

“The issuance of this patent is a major step forward in our international validation for the SpinalCyte technology. This is a significant milestone for us and we are pleased the Chinese Patent Office has validated the uniqueness of our technology which includes 10 U.S. and foreign patents issued and directly owned by the company, along with 34 patents pending,” said Pete O’Heeron, Chief Executive Officer for SpinalCyte. “We feel the future for spinal disc regeneration will be a cell based therapy solution and we continue to build our intellectual property to protect our leading position in this field.”

About SpinalCyte, LLC

Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts. The goal of SpinalCyte is to develop a cartilage regeneration technology using autologous dermal cells harvested from the patient. To date, SpinalCyte has been funded entirely by angel investors.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160108005145/en/

CONTACT

SpinalCyte, LLC
Pete O’Heeron, 281-461-6211
CEO
pete@spinalcyte.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • DSG, Inc. Accelerates Growth with Opening of New Office in Bangalore, India
  • 仁和集团与APR应用制药研究公司公布协议在中国市场销售治疗偏头痛创新药
  • 武田连续第二年入选全球可持续发展最佳企业百强榜单
  • InFo 124M – 瑞士生产的用于白内障手术的延伸焦深人工晶体
  • 2017 Taiwan WHO Simulation Kicks off at NCKU with 240 Medical Students Sharing